Fig. 3: In vivo favorable effect of SLC-D011.

A Gross morphology of Lmna^G609G/G609G mice (10 weeks old) was ameliorated after injection with SLC-D011. At the same age, the experimental group (D011) of mice were larger than vehicle-injected control (Con) subjects regardless of gender. B, C SLC-D011 increases body weight B and extends life span C of Lmna^G609G/G609G progeria model mouse (Con: n = 8; SLC-D011: n = 8). Compared with 14.8 weeks of average (ave) life span with maximum (max) life span of 15.5 weeks, 20 mg/kg of intraperitoneal (i.p) injection (twice a week) of SLC-D011 could extend the life span upto 19 weeks (max = 21 weeks). Lmna^G609G/G609G mice were injected with SLC-D011 from age of 5-week old, *p < 0.05. D Gross morphology of SLC-D011 injected Lmna^G609G/+ mouse. Sickly and weak features were observed in 45 weeks old Lmna^G609G/+ mouse, but not observed in treated mouse, although they had the same age. E SLC-D011 increases body weights of Lmna^G609G/+ mice (Con: n = 10; SLC-D011: n = 11), *p < 0.05. F Favorable effect of SLC-D011 on life span of Lmna^G609G/+ mice. Compared with vehicle-injected control group (ave = 46.7 weeks and max = 48 weeks), SLC-D011 treatment obviously extended the average life span to 63 weeks (max = 64 weeks). The injection was started from 32 weeks old, **p < 0.001. “Con” means vehicle (a solvent composed of DMSO and PBS)-injected mouse group.